The company is currently growing over 1500 acres in Oregon, Kentucky and Colorado. This distributed production allows for the leverage of superior growing methods/conditions while mitigating risk for weather-related variables.
With an average margin of 76% to 88%, Hemptown USA’s initial products include flower, pre-rolls, biomass, distillate and isolate. Several consumer brands are presently in development with launch dates set for fall 2019.
Hemptown USA’s premium genetics allow for unparalleled biomass yielding 12-20% broad spectrum content. This quality leads to increased extraction efficiency and maximum profitability.
Hemptown USA is in the process of acquiring a FDA, cGMP certified facility for the formulation and production of quality consumer-ready products.
CBG is the precursor to the main cannabinoids (THCA, CBDA, CBCA) and is commonly known as “The Mother of All Cannabinoids”. Hemptown USA is growing over 500 acres focused exclusively on these rare genetics, and is projecting to control 40% of total North American supply by 2019 Q4.